At a time of unprecedented need and despite significant advances in understanding brain function and related diseases,the drug pipeline for treatment of mental ill-health is failing[1,2].The reasons are many,including the unparalleled complexity of the central nervous system(CNS)itself,a lack of interdisci-plinary research collaborations,increased drug development costs,and higher risk of clinical failure of CNS drugs compared with other areas of drug development[3-6].